Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;14(12):3335-44.
doi: 10.1245/s10434-007-9449-x. Epub 2007 May 31.

Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic

Bernadette A M Heemskerk-Gerritsen  1 , Cecile T M Brekelmans, Marian B E Menke-Pluymers, Albert N van Geel, Madeleine M A Tilanus-Linthorst, Carina C M Bartels, Murly Tan, Hanne E J Meijers-Heijboer, Jan G M Klijn, Caroline Seynaeve
Affiliations

Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic

Bernadette A M Heemskerk-Gerritsen et al. Ann Surg Oncol. 2007 Dec.

Abstract

Background: BRCA1/2 mutation carriers and women from a hereditary breast(/ovarian) cancer family have a highly increased risk of developing breast cancer (BC). Prophylactic mastectomy (PM) results in the greatest BC risk reduction. Long-term data on the efficacy and sequels of PM are scarce.

Methods: From 358 high-risk women (including 236 BRCA1/2 carriers) undergoing PM between 1994 and 2004, relevant data on the occurrence of BC in relation to PM, complications in relation to breast reconstruction (BR), mutation status, age at PM and preoperative imaging examination results were extracted from the medical records, and analyzed separately for women without (unaffected, n = 177) and with a BC history (affected, n = 181).

Results: No primary BCs occurred after PM (median follow-up 4.5 years). In one previously unaffected woman, metastatic BC was detected almost 4 years after PM (primary BC not found). Median age at PM was younger in unaffected women (P < .001), affected women more frequently were 50% risk carriers (P < .001). Unexpected (pre)malignant changes at PM were found in 3% of the patients (in 5 affected, and 5 unaffected women, respectively). In 49.6% of the women opting for BR one or more complications were registered, totaling 215 complications, leading to 153 surgical interventions (71%). Complications were mainly related to cosmetic outcome (36%) and capsular formation (24%).

Conclusions: The risk of developing a primary BC after PM remains low after longer follow-up. Preoperative imaging and careful histological examination is warranted because of potential unexpected (pre)malignant findings. The high complication rate after breast reconstruction mainly concerns cosmetic issues.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Annual number of PM in unaffected/affected BRCAa/2 mutation carriers and 0% risk carriers from HB(O)C families.
See this image and copyright information in PMC

Comment in

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1126/science.1088759', 'is_inner': False, 'url': 'https://doi.org/10.1126/science.1088759'}, {'type': 'PubMed', 'value': '14576434', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14576434/'}]}
    2. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643–6 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1086/301749', 'is_inner': False, 'url': 'https://doi.org/10.1086/301749'}, {'type': 'PMC', 'value': 'PMC1376944', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1376944/'}, {'type': 'PubMed', 'value': '9497246', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9497246/'}]}
    2. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62:676–89 - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1056/NEJM199705153362001', 'is_inner': False, 'url': 'https://doi.org/10.1056/nejm199705153362001'}, {'type': 'PubMed', 'value': '9145676', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9145676/'}]}
    2. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401–8 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0140-6736(02)11023-3', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0140-6736(02)11023-3'}, {'type': 'PubMed', 'value': '12354469', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12354469/'}]}
    2. Bergfeldt K, Rydh B, Granath F, Gronberg H, Thalib L, Adami HO, Hall P. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet 2002; 360:891–4 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1056/NEJM200107193450301', 'is_inner': False, 'url': 'https://doi.org/10.1056/nejm200107193450301'}, {'type': 'PubMed', 'value': '11463009', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11463009/'}]}
    2. Meijers-Heijboer H, van Geel B, Van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:159–164 - PubMed

MeSH terms